U.S. Stock Market Midday Update
SciSparc fell 18.01%. Based on recent key news:
<ol>
<li>
On May 28, SciSparc's subsidiary NeuroThera Labs received conditional regulatory approval to acquire CliniQuantum. This news led to significant intraday stock price fluctuations, with an increase of over 194%. Source: Benzinga
</li>
<li>
On May 28, SciSparc announced in Tel Aviv that NeuroThera Labs received approval from the TSX Venture Exchange to acquire approximately 54% of CliniQuantum. This move marks the company's strategic expansion in innovative therapies for central nervous system diseases. Source: Zhitong Finance
</li>
<li>
On May 29, SciSparc's stock price rose 157.05% to $11.31, reflecting the market's positive reaction to the acquisition news. Source: Benzinga Pro The pharmaceutical industry has seen frequent acquisition activities recently, leading to increased market volatility.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
Eli Lilly fell 2.95%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 28, CVS Health announced that it would reintroduce Eli Lilly's weight loss drug Zepbound to its preferred drug list and include the new oral medication Foundayo. This move enhances Eli Lilly's competitiveness in the GLP-1 drug market and may positively impact its stock price. Source: CVS Health Official Statement
</li>
<li>
On May 27, Eli Lilly announced a collaboration agreement with German biotech company Seamless Therapeutics, investing $1.1 billion to develop gene therapies. This strategic investment demonstrates Eli Lilly's intent to expand in the gene therapy field, potentially enhancing its long-term competitiveness. Source: Yicai
</li>
<li>
On May 27, Bank of America raised Eli Lilly's target price to $125.1, maintaining a &#34;Buy&#34; rating, believing that market demand for its obesity and diabetes treatment drugs will continue to grow. This move may boost investor confidence. Source: Gelonghui The competition in the GLP-1 drug market is intensifying, with significant macroeconomic impacts.
</li>
</ol>
Johnson &amp; Johnson fell 1.84%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 29, Johnson &amp; Johnson released data on its new drug TECVAYLI, showing superior progression-free survival and overall survival in the treatment of multiple myeloma. This positive result may boost market confidence in the company's future growth, but it failed to offset overall market pressure, leading to a stock price decline. Source: JNJ Stock News
</li>
<li>
On May 29, market analyst Cramer recommended Johnson &amp; Johnson as one of the stocks with strong fundamentals, despite geopolitical tensions and inflationary pressures in the market. The stable bond market and potential Federal Reserve rate cuts bring optimism to the market. Source: Cramer’s bullish picks
</li>
<li>
On May 29, Johnson &amp; Johnson's investor conference call is scheduled for July 15, and the market is taking a wait-and-see attitude towards the upcoming second-quarter results, which may affect short-term stock price fluctuations. Source: Public Technologies (PUBT) The pharmaceutical industry is driven by innovation for growth, with macroeconomic stability.
</li>
</ol>
Merck fell 1.13%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 29, Merck's Calderasib received FDA breakthrough therapy designation for patients with KRAS G12C mutation non-small cell lung cancer. This news drove stock price fluctuations as market expectations for the new therapy increased. Source: MT Newswires
</li>
<li>
On May 27, Merck announced that its avian bronchitis vaccine received approval from the Ministry of Agriculture of China. This move may enhance the company's position in the global vaccine market and affect investor confidence. Source: Reuters
</li>
<li>
On May 28, UBS increased Merck's portfolio weight due to its exposure to longevity trends. This move may boost market expectations for Merck's long-term growth. Source: UBS The pharmaceutical industry is significantly influenced by longevity trends.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
AstraZeneca rose 0.18%, with increased trading volume. Based on recent key news:
<ol>
<li>
On May 28, AstraZeneca deepened cooperation with the Wuxi municipal government to fully implement previously agreed cooperation matters, enhancing market confidence. Source: Jin10 Data
</li>
<li>
On May 29, AstraZeneca signed a strategic cooperation agreement with Synlogic, paying a $420 million upfront payment, improving the company's financial condition. Source: People's Financial News
</li>
<li>
On May 29, AstraZeneca's Benralizumab new indication was approved for market launch, expanding market potential. Source: Zhito Finance The pharmaceutical industry's cooperation and innovation drive stock price fluctuations
</li>
</ol>

SPRC

SciSparc fell 18.01%; Eli Lilly fell 2.95%, with a transaction volume of $1.375 billion; Johnson & Johnson fell 1.84%, with a transaction volume of $644 million; Merck fell 1.13%, with a transaction volume of $329 million; AstraZeneca rose 0.18%, with a market value of $288 billion

Price Alert

SciSparc

U.S. stock market midday update: SciSparc down 18.01%: profit-taking after acquisition approval, high volatility risk reappears